GT Healthcare Capital Partners (“GT Healthcare”), a life science-focused private equity partnership which specializes in capital investments and market scalability in Asia/ Greater China region, has launched an AI-driven drug development company in SHANGHAI, June 1, 2019— GT Apeiron Therapeutics (“Apeiron Therapeutics”)
SHANGHAI, June 1st, 2019 GT Healthcare Capital Partners (“GT Healthcare”)has launched an AI-driven drug development company in Shanghai with $27 million financial backing today– GT Apeiron Therapeutics (“Apeiron”), a novel biotechnology company, was launched with the backing from GT Healthcare and associated investors.
Apeiron will target cancer as top priority, and cooperate with partners around the world to address the medical issues that have not yet been resolved, which are fatal and seriously affect the life quality of patients. Apeiron aims to accelerate the development of novel drugs via new pathways to tackle high impact therapeutic targets, with an initial focus on oncology.
“Though pharmaceutical R&D productivity has been a challenge for the industry, we have seen positive trends such as breakthroughs in biology, novel approaches, and acceleration of technology advances. Apeiron will leverage such emerging technologies to significantly improve drug R&D productivity to benefit patients,” Dr. Mingxi Li said in an interview at the launch. He is a Partner at GT Healthcare and a board member of Apeiron.
Led by a team with extensive drug discovery expertise, Apeiron intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence, which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials.
We are launching GT Apeiron at a time of rapid AI-powered tools development underpinning new drug development,” said Dave Norwood, Advisory Board Chairman of Apeiron. “I am delighted to see a highly-devoted team, leveraging on latest technologies to efficiently develop new drugs tackling difficult-to-drug targets and to address huge unmet medical needs globally.”